Education
About Us
Working with TipRanks
Follow Us
Ovid Therapeutics Inc (OVID)
NASDAQ:OVID
OVID Stock Chart & Stats
$1.91
-$0.03(-2.93%)
At close: 4:00 PM EST
$1.91
-$0.03(-2.93%)
Day’s Range― - ―
52-Week Range$0.24 - $2.01
Previous CloseN/A
Volume22.63K
Average Volume (3M)1.43M
Market Cap
$248.65M
Enterprise Value$129.17M
Total Cash (Recent Filing)$25.60M
Total Debt (Recent Filing)$13.76M
Price to Earnings (P/E)―
Beta2.28
Next Earnings
Mar 16, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding130,184,360
10 Day Avg. Volume1,405,714
30 Day Avg. Volume1,429,408
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.97
Price to Sales (P/S)116.97
P/FCF Ratio-1.18
Enterprise Value/Market Cap0.52
Enterprise Value/Revenue19.54
Enterprise Value/Gross Profit19.59
Enterprise Value/Ebitda-3.21
Forecast
1Y Price Target
$3.25Price Target Upside70.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.45
Revenue Forecast (FY)$174.13K
Bulls Say, Bears Say
Bulls Say
Clinical Trial Safety For OV329Phase 1 biomarker and safety results for OV329, including no ophthalmic safety findings, indicate a relatively derisked clinical profile as the program moves toward a Phase 2a study.
KCC2 Mechanism ValidationFirst-in-human data for KCC2 activators demonstrated a clean safety profile and EEG changes consistent with target engagement, supporting validation of a novel mechanism for seizure control.
Therapeutic Differentiation And Market PotentialOV329's unique mechanism and KCC2 modulators' potential to boost the effectiveness of existing therapies such as benzodiazepines position the pipeline to address unmet needs in drug-resistant epilepsy.
Bears Say
Historical Late-stage Execution RiskA track record that includes multiple late-stage program failures underscores execution and commercialization risk for future candidates from the company.
Lead Optimization And Off-target RiskPlans to switch to a different lead molecule highlight remaining off‑target risk for small‑molecule programs and could introduce development delays while selectivity and safety are revalidated.
Treatment-emergent Adverse EventsThe most frequent treatment-emergent adverse event with OV350 was headache, which could affect tolerability and patient adherence if it persists in later studies.
Ovid Therapeutics News
OVID FAQ
What was Ovid Therapeutics Inc’s price range in the past 12 months?
Ovid Therapeutics Inc lowest stock price was $0.24 and its highest was $2.01 in the past 12 months.
What is Ovid Therapeutics Inc’s market cap?
Ovid Therapeutics Inc’s market cap is $248.65M.
When is Ovid Therapeutics Inc’s upcoming earnings report date?
Ovid Therapeutics Inc’s upcoming earnings report date is Mar 16, 2026 which is in 7 days.
How were Ovid Therapeutics Inc’s earnings last quarter?
Ovid Therapeutics Inc released its earnings results on Nov 12, 2025. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.15 by -$0.02.
Is Ovid Therapeutics Inc overvalued?
According to Wall Street analysts Ovid Therapeutics Inc’s price is currently Undervalued.
Does Ovid Therapeutics Inc pay dividends?
Ovid Therapeutics Inc does not currently pay dividends.
What is Ovid Therapeutics Inc’s EPS estimate?
Ovid Therapeutics Inc’s EPS estimate is -0.12.
How many shares outstanding does Ovid Therapeutics Inc have?
Ovid Therapeutics Inc has 130,184,360 shares outstanding.
What happened to Ovid Therapeutics Inc’s price movement after its last earnings report?
Ovid Therapeutics Inc reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.15. Following the earnings report the stock price went down -2.222%.
Which hedge fund is a major shareholder of Ovid Therapeutics Inc?
Currently, no hedge funds are holding shares in OVID
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ovid Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.25 (70.16% Upside)
$3.25 (70.16% Upside)
Blogger Sentiment
Bullish
OVID Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 9.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.1%
Last 30 Days ▼ 4.3%
Last 30 Days ▼ 4.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
268.72%
12-Months-Change
Fundamentals
Return on Equity
-60.06%
Trailing 12-Months
Asset Growth
-37.80%
Trailing 12-Months
Company Description
Ovid Therapeutics Inc
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
OVID Stock 12 Month Forecast
Average Price Target
$3.25
▲(70.16% Upside)
Technical Analysis
Opus Genetics
―
Zentalis Pharmaceuticals
―
Inhibikase Therapeutics
―
Surrozen
―
Biomea Fusion
―
Ownership Overview
9.73% Insiders
5.74% Mutual Funds
10.34% Other Institutional Investors
72.07% Public Companies and Individual Investors